Detection and Therapeutic Implications of c-Met Mutations in Small Cell Lung Cancer and Neuroendocrine Tumors

J. Voortman, T. Harada, R. P. Chang, J. K. Killian, M. Suuriniemi, W. I., Jr. Smith, P. S. Meltzer, M. Lucchi, Y. Wang, G. Giaccone

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)833-840
JournalCurrent Pharmaceutical Design
Volume19
Issue number5
Publication statusPublished - Feb 2013

Keywords

  • c-Met
  • mutation
  • neuroendocrine tumor
  • tyrosine kinase inhibitor

Cite this